Literature DB >> 23255566

Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever.

Lauren M Smith1, Lisa E Hensley, Thomas W Geisbert, Joshua Johnson, Andrea Stossel, Anna Honko, Judy Y Yen, Joan Geisbert, Jason Paragas, Elizabeth Fritz, Gene Olinger, Howard A Young, Kathleen H Rubins, Christopher L Karp.   

Abstract

There is a clear need for novel, effective therapeutic approaches to hemorrhagic fever due to filoviruses. Ebola virus hemorrhagic fever is associated with robust interferon (IFN)-α production, with plasma concentrations of IFN-α that greatly (60- to 100-fold) exceed those seen in other viral infections, but little IFN-β production. While all of the type I IFNs signal through the same receptor complex, both quantitative and qualitative differences in biological activity are observed after stimulation of the receptor complex with different type I IFNs. Taken together, this suggested potential for IFN-β therapy in filovirus infection. Here we show that early postexposure treatment with IFN-β significantly increased survival time of rhesus macaques infected with a lethal dose of Ebola virus, although it failed to alter mortality. Early treatment with IFN-β also significantly increased survival time after Marburg virus infection. IFN-β may have promise as an adjunctive postexposure therapy in filovirus infection.

Entities:  

Keywords:  Ebola virus; Filovirus; IFN-β; Marburg virus; type I interferon

Mesh:

Substances:

Year:  2012        PMID: 23255566      PMCID: PMC3685222          DOI: 10.1093/infdis/jis921

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  46 in total

1.  Marburg hemorrhagic fever associated with multiple genetic lineages of virus.

Authors:  Daniel G Bausch; Stuart T Nichol; Jean Jacques Muyembe-Tamfum; Matthias Borchert; Pierre E Rollin; Hilde Sleurs; Patricia Campbell; Florimund K Tshioko; Catherine Roth; Robert Colebunders; Patricia Pirard; Simon Mardel; Loku A Olinda; Hervé Zeller; Antoine Tshomba; Amayo Kulidri; Modeste L Libande; Sabue Mulangu; Pierre Formenty; Thomas Grein; Herwig Leirs; Leo Braack; Tom Ksiazek; Sherif Zaki; Michael D Bowen; Sheilagh B Smit; Patricia A Leman; Felicity J Burt; Alan Kemp; Robert Swanepoel
Journal:  N Engl J Med       Date:  2006-08-31       Impact factor: 91.245

2.  Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses.

Authors:  T W Geisbert; L E Hensley; T R Gibb; K E Steele; N K Jaax; P B Jahrling
Journal:  Lab Invest       Date:  2000-02       Impact factor: 5.662

3.  Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever.

Authors:  Mike Bray; Thomas W Geisbert
Journal:  Int J Biochem Cell Biol       Date:  2005-03-07       Impact factor: 5.085

Review 4.  Complex modulation of cell type-specific signaling in response to type I interferons.

Authors:  Anette H H van Boxel-Dezaire; M R Sandhya Rani; George R Stark
Journal:  Immunity       Date:  2006-09       Impact factor: 31.745

Review 5.  Incorporation of gene ontology annotations to enhance microarray data analysis.

Authors:  Michael F Ochs; Aidan J Peterson; Andrew Kossenkov; Ghislain Bidaut
Journal:  Methods Mol Biol       Date:  2007

Review 6.  Post-transcriptional control of the interferon system.

Authors:  Khalid S A Khabar; Howard A Young
Journal:  Biochimie       Date:  2007-02-24       Impact factor: 4.079

7.  Comparison of non-human primate and human whole blood tissue gene expression profiles.

Authors:  James F Dillman; Christopher S Phillips
Journal:  Toxicol Sci       Date:  2005-06-23       Impact factor: 4.849

8.  Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection.

Authors:  E Stylianou; P Aukrust; K Bendtzen; F Müller; S S Frøland
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

9.  Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection.

Authors:  F Villinger; P E Rollin; S S Brar; N F Chikkala; J Winter; J B Sundstrom; S R Zaki; R Swanepoel; A A Ansari; C J Peters
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

10.  Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections.

Authors:  P B Jahrling; T W Geisbert; J B Geisbert; J R Swearengen; M Bray; N K Jaax; J W Huggins; J W LeDuc; C J Peters
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

View more
  50 in total

1.  Kinetic Analysis of Biomarkers in a Cohort of US Patients With Ebola Virus Disease.

Authors:  Anita K McElroy; Jessica R Harmon; Timothy D Flietstra; Shelley Campbell; Aneesh K Mehta; Colleen S Kraft; Marshall G Lyon; Jay B Varkey; Bruce S Ribner; Christopher J Kratochvil; Peter C Iwen; Philip W Smith; Rafi Ahmed; Stuart T Nichol; Christina F Spiropoulou
Journal:  Clin Infect Dis       Date:  2016-06-27       Impact factor: 9.079

2.  Ebola: history, treatment, and lessons from a new emerging pathogen.

Authors:  Kevin S Harrod
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-12-12       Impact factor: 5.464

3.  Non-specific anti-viral approach towards Ebola virus infection: a comment on "Against Ebola: type I interferon guard risk and mesenchymal stromal cell combat sepsis".

Authors:  Beuy Joob; Viroj Wiwanitkit
Journal:  J Zhejiang Univ Sci B       Date:  2015-03       Impact factor: 3.066

Review 4.  Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak.

Authors:  Gary Wong; Gary P Kobinger
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

5.  Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.

Authors:  Adrián Lázaro-Frías; Sergio Gómez-Medina; Lucas Sánchez-Sampedro; Karl Ljungberg; Mart Ustav; Peter Liljeström; César Muñoz-Fontela; Mariano Esteban; Juan García-Arriaza
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

Review 6.  Clinical Evaluation of Ebola Virus Disease Therapeutics.

Authors:  Guodong Liu; Gary Wong; Shuo Su; Yuhai Bi; Frank Plummer; George F Gao; Gary Kobinger; Xiangguo Qiu
Journal:  Trends Mol Med       Date:  2017-08-17       Impact factor: 11.951

Review 7.  Epidemiology and Management of the 2013-16 West African Ebola Outbreak.

Authors:  M L Boisen; J N Hartnett; A Goba; M A Vandi; D S Grant; J S Schieffelin; R F Garry; L M Branco
Journal:  Annu Rev Virol       Date:  2016-08-15       Impact factor: 10.431

8.  Pathophysiology of Ebola Virus Infection: Current Challenges and Future Hopes.

Authors:  Andrea Rivera; Ilhem Messaoudi
Journal:  ACS Infect Dis       Date:  2015-03-30       Impact factor: 5.084

Review 9.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

10.  A Recombinant Adenovirus Expressing Ovine Interferon Tau Prevents Influenza Virus-Induced Lethality in Mice.

Authors:  V Martín; E Pascual; M Avia; G Rangel; A de Molina; A Alejo; N Sevilla
Journal:  J Virol       Date:  2016-01-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.